Bristol

JUN 24, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Eliquis (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval action for labeling changes to apixaban (Eliquis); does not report clinical trial outcomes or comparative efficacy data.

APR 27, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Pomalyst (REMS)

U.S. Food and Drug Administration

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide; establishes regulatory requirements but does not report clinical efficacy or safety trial outcomes.

MAR 25, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Krazati (Labeling)

U.S. Food and Drug Administration

This is an FDA supplemental approval action for a labeling change to adagrasib; it documents an administrative decision, not clinical efficacy or safety data.